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The mechanisms that allow the long-term survival of major histocompatibility 
complex (MHC)Limmunologically enhanced organ allografts are poorly under- 
stood (1-5).  In rodents, enhancement can be induced by treatment  with either 
hyperimmune serum at the time of grafting or prior immunization  with donor 
ailoantigen.  After a  treatment  rejection episode, many of these rats  develop a 
state  in  which  the  immune  system capacity of the  host to develop a  rejection 
response is specifically inhibited (1-5). Specific unresponsiveness to donor strain 
alloantigen  in  animals  with  established  enhanced  grafts  is  manifested  by  an 
inability to reject directly vascularized organ grafts from a second donor strain, 
but a normal capacity to reject third party grafts (3-6). Also, in rats with enhanced 
grafts,  the  rejection of donor strain  but not third  party skin  grafts,  is delayed 
and the length of the delay is inversely related to the time after grafting (7). This 
suggests that these animals have a specific inhibitory response that matures with 
time. 
Although  the  induction  of enhancement  is  antibody  mediated,  attempts  to 
demonstrate humoral mediators during the maintenance phase of enhancement 
have been unsuccessful. After passive enhancement, grafts survive long after the 
injected antibody has been metabolized, and in recipients with actively enhanced 
grafts, the alloantibody titers wane after the first month (3, 8). Serum from rats 
with  enhanced  grafts  will  not  enhance  graft  survival  in  a  second  host,  and 
attempts to identify antiidiotype or blocking antibodies in the serum have mostly 
been  unsuccessful  (2,  9-12).  Attempts  to  identify  the  cellular  basis  of  this 
inhibitory  response,  which  maintains  prolonged  graft  survival,  have  thus  far 
failed to demonstrate  a  suppressor cell mechanism.  Hendry et al.  (13) demon- 
strated a specific suppressor cell in thymus and spleen of rats during the induction 
phase of enhancement, but this effect, which could be transferred to nonimmu- 
nosuppressed rats, waned with time and was not demonstrated in the maintenance 
phase. Fabre and Morris (9) adoptively transferred spleen cells from rats bearing 
enhanced  kidney allografts  to normal  rats  grafted  with  kidney allografts,  but 
they failed to transfer enhancement. Batchelor et al. (14) also failed to adoptively 
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transfer  unresponsiveness to partially immunosuppressed  rats that had skin as 
the indicator graft. In all these systems, the adoptive host had a complement of 
lymphocytes adequate  to  effect  rejection  of  the  indicator  graft.  Thus,  any 
suppressor cells would have had to overcome the alloreactivity of these normal 
lymphocytes. 
Suppressor cells have been demonstrated in a wide variety of immune responses 
including some alloimmune responses (15-17).  Dorsch and Roser (15)  showed 
that  in  rats  with  transplantation  tolerance  induced  in  the  neonatal  period, 
recirculating T  cells can adoptively transfer unresponsiveness to irradiated rats 
but not to normal rats. In animals with specific unresponsiveness to grafts, akin 
to enhancement but induced by nonspecific immunosuppression, such as antilym- 
phocyte globulin (ALG) or cyclosporine treatment, suppressor T  cells have also 
been demonstrated by adoptive transfer of spleen cells to irradiated hosts (16, 
17). 
To maximize the chance of identifying a  suppressor mechanism in the main- 
tenance phase of passively induced, enhanced heart grafts, we tested the capacity 
of cells from these animals to adoptively transfer unresponsiveness to irradiated 
heart-grafted hosts. In this model, adoptive transfer of normal cells will restore 
rejection (18). Thus, it was possible to examine whether cells from rats with long- 
surviving grafts had any specific changes in their capacity to effect rejection by 
adoptively transferring them to irradiated syngeneic recipients grafted with the 
original donor strain or third party strain hearts.  A  preliminary report  of this 
work has been published (19). 
Materials and Methods 
Rats.  PVG (RTIC), DA (RTIa),  and Lew (RTF) Strains and (DA  ×  PVG)F~ hybrids 
were bred and maintained at the Animal House, McMaster University, Hamilton, Ontario, 
Canada. The breeding pairs were kindly donated by Dr. A. Williams of the Sir William 
Dunn School of Pathology, Oxford, United Kingdom. AUG (RTI  c) strain were kindly 
donated by Dr. D. B. Wilson, Wistar Institute, Philadelphia. 
Operative Procedures.  Recipient rats, anesthetized by ether, were grafted with PVG 
hearts by end-to-side anastomosis of ascending aorta to abdominal aorta and pulmonary 
artery to inferior vena cava using 7-0 silk (Davis and Geck, Pearl River, NY), as~ previously 
described (20). Graft ischemic times ranged from 25 to 40 rain and all grafts commenced 
to contract within 2 min of revascularization. Graft function was monitored daily and 
rejection was determined by the loss of palpable contractions and confirmed by the loss 
of electrocardiogram activity. Recipients were 250-300-g males and donors were 150- 
200-g females. Skin grafts were performed as described elsewhere (15). 
Induction of Enhancement.  Hyperimmune sera was made by applying a PVG skin graft 
to DA rats, then boosting three times with 5 X 107 PVG spleen cells given intraperitoneally 
every 14 d. These animals were bled out 7 d after the last booster injection and the blood 
was pooled and clotted. The serum, which had cytotoxic titers to PVG of 1:64-1:256, 
was frozen at 20°C until used. Enhancement was induced by giving 1 ml of hyperimmune 
serum intravenously to DA rats at the time of grafting with (DA X PVG) F~ hybrid hearts. 
Rejection time was always delayed from a normal period of 6-10 d, but many rats did 
have a  rejection  crisis  10-21  d  after transplant.  In  two-thirds of the rats,  the  grafts 
recovered from the rejection. Only those rats with hearts surviving >75 d were used as 
cell donors for the adoptive transfer experiments. 
Cell Separation.  Single-cell suspensions were prepared from spleen or pooled cervical 
and mesenteric lymph node cells (LNC) by gently squeezing them between the flat bottom 
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temperature in Dulbecco's phosphate-buffered saline containing calcium, magnesium, and 
bovine serum albumin (0.06%) (Armour Pharmaceutical Co. Ltd., Hampden Park, East- 
bourne, Sussex, United Kingdom), preparations had a viability of 85-95% by trypan blue 
exclusion. 
In Vitro Cell Preparation.  The rosetting technique described by Parish and Hayward 
(21) was used. Briefly, goat anti-rat globulin (lot 4544; Cappel Laboratories, Cochranville, 
PA) was fixed to fresh sheep red blood cells using CrCis and these cells formed rosettes 
with  rat  lymphocytes bearing  surface  immunoglobulin  (sIg  ÷ cells).  The  nonrosetted 
lymphocytes were separated off on Ficoll (Pharmacia Fine Chemicals, Uppsala, Sweden) 
Hypaque  (Winthrop  Laboratories,  Aurora,  Ontario,  Canada),  specific gravity,  1.098. 
These preparations contained <5% slg  ÷ cells as assessed by staining with fluorescent goat 
anti-rat Ig (lot 8549A; Cappel Laboratories) using the labeling method described previ- 
ously (16). More than 500 cells were examined with a Dialux microscope (E. Leitz, Inc., 
Rockleigh, N  J) fitted with Ploempak incident-light fluorescence and combined transmitted 
light phase contrast optics. 94-97% carried the peripheral T  cell antigen Pta, A2, and B 
(22), which was detected by AUG anti-PVG antiserum, prepared according to the method 
of Howard and Scott (22) and used in two-stage immunofluorescence technique (18). 
Recirculating T Cells.  These were prepared as previously described (15,  18). Briefly, 
1.5  X  109 spleen cells from DA rats with enhanced (DA X PVG)F~ hybrid heart grafts 
were injected intravenously into intermediate hosts, which were DA rats that had been 
exposed to 1,000 rad whole body irradiation, had had their thoracic duct cannulated, and 
had been splenectomized. Cells  were collected from the thoracic duct cannula of these 
rats for 36 h after their injection with spleen cells. These recirculating cells, 98% of which 
were Pta, A2, and B, and 2% sIg  ÷ cells,  were tested in the adoptive transfer assay  for 
their capacity to restore rejection. 
Complement-dependent Cytotoxic Antibody Titers.  These were performed essentially as 
described previously using PVG LNC as targets and guinea pig sera as complement (18). 
The endpoint was 50% killed cells. 
Experimental Design.  The adoptive transfer assay  used has been described in detail 
(18). PVG or Lew hearts were grafted into DA recipients <24 h after both the donor and 
recipient rats had been exposed to 750 rad from a 6°Co source of a rate of 100-120 rad/ 
min. Groups of rats grafted with PVG and Lew hearts were given intravenous injections 
of similar inocula of lymphoid cells. The speed of graft rejection was compared between 
these groups. Differences were analyzed using the Wilcoxon rank sum test and P <  0.05 
was considered a significant difference. Results are expressed throughout as mean rejec- 
tion time _  SD (in days). 
Results 
Capacity of  LNC to Adoptively Restore Heart Graft Rejection in Irradiated Rats.  In 
previous  studies  (18,  23),  we  have  shown  that  LNC  from  normal  rats  will 
adoptively restore graft rejection in irradiated rats, and that the time taken to 
reject the graft is  inversely related to the  number of cells in  the  inoculum.  A 
given  inoculum  has  a  similar  restorative  effect on  PVG  or  Lew  heart  graft 
rejection  (see  Table  I).  This assay  was  used  to detect  any specific changes  in 
alloreactivity of LNC from DA rats with enhanced (DA x  PVG)F1 hybrid heart 
grafts that had functioned for at least 75  d.  Inocula of 1.5  x  108 and  5  x  107 
LNC cells from these rats  restored PVG graft rejection, but with a  small and 
significant delay compared with the rejection time in rats restored with similar 
numbers of normal LNC. 5  x  107  LNC from rats with enhanced grafts effected 
Lew graft rejection at the same rate as normal LNC.  With  2  X  107  LNC, four 
of six  PVG grafts were not rejected in  100 d, but Lew grafts were all rejected 
and at the same  rate as occurred with  2  x  107  normal  LNC.  Control rats  not 
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TABLE  I 
Heart Graft Survival  Time in Irradiated  DA Rats Restored with LNC for Either DA With Enhanced 
(DA x PVG) FI PVG Heart Grafts or Normal DA Rats 
Restorative  inocula  Rejection  time of PVG grafts 
Significance 
Rejection time of Lew grafts 
Number  Source  Days  Mean 4- SD  Days  Mean +  SD 
1.5 X  108  Enhanced  10, 12, 14,  15, 16  13.4 +  2.4  P  <  0.05  --  --  ND* 
1.5 ×  l0 s  Normal  8(2), 9(2), 10,  9.75 +  1.5  NSD  ~  8, 9,  10, 12  9.75 +  1.7 
11(2),  J2 
5  ×  107  Enhanced  11, 13, 15, 17, 18  14.8 4-2.9  P<  0,01  NSD  9,  11, 13(2), 15  12.2 4- 2,3 
5  x  107  Normal  9(2), 10(2), 11(3)  10.1 4- 0.9  NSD  9,  10, 12, 13, 14,  12,6 ±  2.8 
15, 16 
2  x  107  Enhanced  25, 28, >80(4)  >80  P  <  0.05  P  <  0.05  16, 19, 23(2), 25  21.2 4- 3.6 
2  X  107  Normal  12, 19, 23, 25  25.4 -+ 4.5 
--  --  46, 54, 63, 75, 92  66 -+ 18.1  NSD  62, 67, 69, 74,  >79 
79, > 100(2) 
* Not determined. 
* No significant difference. 
TABLE  II 
Heart Graft Survival Time in Irradiated DA Rats Restored  With Spleen Cells from Either DA With 
Enhanced (DA × PVG) F1 Heart Grafts or Normal DA Rats 
Restorative  inocula  Rejection time of PVG grafts  Rejection  time of Lew grafts 
Number of  Significance 
Source  Days  Mean -+ SD  Days  Mean +  SD 
LNC 
1.5x  10 s  Enhanced  40, 49, >100(4)  >100  <0.01  11, 14, 16, 18,20  15.84-3.5 
1.5 ×  10 s  Normal  12, 14, 16(3), 18(2),  16.3 +  2.5  <0.001  --  ND 
20 
7.5 X  107  Enhanced T  15, 21, 25, >100(4)  >100  <0.05  <0.01  10, 12, 13, 15, 16  13.2 +  2.4 
7.5 x  107  Normal T  13, 15, 17, 19, 21  14.6 +  2.7  ND 
As over 5  x  108  LNC can be obtained from rats with enhanced grafts, these 
experiments  show  that  these  rats  have  a  surplus  of cells  with the  capacity  to 
mediate PVG rejection.  The small reduction in the capacity of LNC from rats 
with enhanced  (DA  X  PVG)F1  grafts to effect PVG rejection was shown to be 
specific  by  the  finding  that  they  restored  Lew  rejection  to  the  same  rate  as 
normal LNC (Table I). 
These results suggest that either there was a relative deficiency in the propor- 
tion of alloreactive cells to PVG compared with Lew, which is best manifested 
with  the  smaller  inocula  of  2  x  107  LNC,  or  that  some  specific  inhibitory 
mechanisms may have overridden the effector cells in the smaller inocula. 
Capacity of Spleen Cells to Adoptively Restore Heart Graft Rejection in Irradiated 
Rats.  Spleen cells from rats with long-surviving grafts showed a marked, specific 
loss in capacity to restore PVG graft rejection (Table II).  1.5  x  10 a spleen cells 
failed to restore rejection in  the  time a  similar number of normal spleen cells 
can. In four of six rats, PVG graft rejection was not effected, and the other two 
did not reject their grafts until >40 d.  Loss of reactivity was specific in that  1.5 
x  108  spleen  cells  from  rats  with  enhanced  grafts  effected  third  party  graft 
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TABLE  Ill 
Graft Survival Time of Heart Grafts in Irradiated DA Rats Restored with Recirculating T 
Cells Obtained  from Spleen Cells of DA Rats with Enhanced (DA × PVG) F I Grafts 
Number of cells  Donor strain  Rejection time (days)  Mean ___ SD  Significance 
1.5 X  10 7  PVG  11,  13,  15,  17(2)  14.6--  +  2.6 
NSD  1.5 x  10 7  Lew  10,  11(2),  15(2)  12.4 +  2.4 
rejected PVG grafts within  100 d.  Larger inocula (4 ×  108) also did not effect 
rejection when tested in two rats. 
To examine whether the failure of spleen cells to adoptively restore rejection 
was due to a loss of ailoreactivity of the T  cell fraction of the spleen, we depleted 
the spleen cells of Ig  + cells using a  rosetting technique.  Cell fractions prepared 
in this way were 95-99% Pta  ÷ and 2-5% sIg+~ compared with 45-50% Pta  + and 
50-55% sIg  ÷ in unfractionated spleens. 7.5 x  107 T  cells, which is equivalent to 
the number of T  cells in  1.5  x  10 s unfractionated  spleen cells, were tested in 
the adoptive transfer assay. These T  cell fractions of spleen also showed a specific 
lack  of capacity to adoptively restore  PVG  graft  rejection,  but  had  a  normal 
capacity to restore  Lew graft  rejection  (Table II).  Cell for ceil,  normal  spleen 
cells are  less effective than  LNC at restoring graft rejection,  in that  1.5  x  l0 p 
spleen cells only restore rejection to <20 d  and  1.5  ×  l0 s LNC to <10 d.  We 
have previously shown  (18)  that  in  spleen and  LNC,  the  cells that  adoptively 
restore rejection are T  cells of the recirculating pool and that the difference in 
capacity of these cell populations  to restore  rejection  is related  to the  smaller 
proportion of recirculating T  cells in the spleen. 
Capacity  of Recirculating  T  Cells  to adoptively  Restore Heart Graft Rejection  in 
Irradiated Rats.  In rats with neonatally induced transplantation  tolerance,  the 
recirculating  T  cells contain  suppressor cells that adoptively transfer  tolerance 
to irradiated hosts (15). To test whether the spleens of rats with enhanced grafts 
were depleted of recirculating alloreactive T  cells, or contained a  recirculating 
suppressor  T  cell  similar  to that  found  in  neonatal  tolerance,  recirculating  T 
cells were prepared  as described  in  Materials  and  Methods and  these  inocula 
were essentially nearly all T  cells (98% Pta  ÷, 2% sIg+).  There was no difference 
in their capacity to adoptively restore both PVG and Lew graft rejection (Table 
III). Thus,  spleen from rats with enhanced grafts do have recirculating  T  cells 
with a normal capacity to adoptively restore graft rejection. 
These studies suggest that  within  the cell  fraction of spleen, there may be a 
suppressor  population  that  inhibits  the  capacity  of the  recirculating  T  cells 
present in the spleen to effect the rejection response. 
Capacity  of Spleen  Cells  to Inhibit  Normal  LNC  Capacity  to  Adoptively  Restore 
Heart Graft Rejection  in Irradiated Rats.  Spleen  cells and  splenic T  cells were 
tested for their capacity to inhibit  the restoration  of graft rejection by normal 
LNC. As the ratio of suppressor to effector cells may be critical, an inoculum of 
normal  LNC (3  X  107),  which only partially restored ~'ejection to normal,  was 
mixed with  1.5  x  10  s spleen cells from rats  with enhanced  grafts.  The spleen 
cells inhibited the capacity of the normal LNC to effect rejection (Table IV). 
The capacity of T  cells to mediate this effect was also tested. Inocula of 7.5 x 128  MECHANISMS  MAINTAINING  ENHANCEMENT  OF  ALLOGRAFTS 
TABLE IV 
PVG Heart Graft Survival  Times in Irradiated DA Rats Restored with Spleen Cells or In 
Vitro-Separated T Cell Fraction of Spleen Cells  from DA Rats with Enhanced (DA × PVG) F I 
Heart Grafts and Normal LNC 
Number of cells from 
Enhanced  Normal 
spleen  LNC 
Rejection time (days)  Mean ±  SD  Significance 
1.5 x  10 s  --  55, >100(5)  >100  NSD 
1.5 x  l0  s  3 ×  107  41, 56, >100(4)  >100  NSD 
7.5 x  107 T  --  26, 32, >100(4)  >100  NSD 
7.5 x  107 T  3 x  107  20, 23, 27, 30, 34(2)  28.0 ±  5.8  P <  0.001 
--  3  ×  107  14,  16(4),  18, 19(4)  17.2 ±  1.8  P<  0.001 
--  --  46, 51, 56, 61, 66, 80  60.0 +  12.1 
107 T  cells prepared  by rosetting also significantly delayed the capacity of the 
normal LNC to restore rejection but never established a  state of enhancement, 
as all grafts were eventually rejected (Table IV). This suggests that the T  cells 
in spleen only partially mediate suppression and that other mechanisms, including 
antibody-mediated responses, may contribute to mediation. 
Cytotoxic Antibody Response in Adoptively Restored Rats.  Rats restored with  1.5 
×  108 spleen cells from enhanced rats and 3 ×  107 normal LNC were tested for 
cytotoxic  antibodies  7,  14,  and  28  d  after  their  restoration.  No  detectable 
antibody was found. Control irradiated  DA rats restored with 1.5 ×  108 normal 
spleen cells had antibody titers of 1:16 to 1:64 at 7 d, and  1:32 to 1:128 at 14 d. 
Control hyperimmune sera always had a cytotoxicity of 1:64 to 1:256. The target 
for these assays was PVG LNC, 40% of which are B cells. In none of the assays 
of sera from rats adoptively restored with cells from rats with enhanced  grafts 
was the  cytotoxicity of the  LNC  above background.  An antibody response  to 
class II MHC antigens detectable by cytotoxicity to B cells was also not identified. 
Thus, the capacity of spleen cells to inhibit the normal LNC capacity to restore 
rejection could not be ascribed to a transfer of complement-dependent cytotoxic 
antibody response to conventional class I or class II MHC antigens. 
Immune  Status  of Rats  Adoptively  Restored  with  Spleen  Cells from  Rats  With 
Enhanced  Grafts.  Four  DA  rats  that  had  been  irradiated  and  restored  with 
spleen cells from DA rats with enhanced  grafts and had had  PVG heart grafts 
surviving for over 75 d were tested for their alloreactivity by skin-grafting them 
with PVG and Lew grafts. PVG skin grafts were not rejected at the first-set rate, 
as one rejected the graft in  13 d, one in 23 d, and the other two retained their 
grafts for over 80 d. The first-set rejection rate for PVG on normal DA rats is 
8-10 d.  In contrast,  Lew skin was rejected in  8,  9,  and  10 (2) d,  respectively, 
which is at the first-set rate (8-11 d). All four rats retained l~heir PVG heart graft 
and there was no detectable rejection crisis at the time the PVG skin was rejected. 
In  another  group  of rats  adoptively restored  with  spleen cells from rats with 
enhanced grafts, where PVG grafts surviving >75 d  were challenged with 2  x 
108  normal  LNC,  these  cells  also  failed  to  effect  rejection  and  all  aliografts 
continued  to function  for  another  50  d.  These  experiments  suggest  that  the 
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similar to that seen in normal rats in which graft survival has been enhanced 
with antisera. 
Discussion 
These experiments showed that rats with passively enhanced, long-surviving 
cardiac allografts had sufficient recirculating T  cells with reactivity toward the 
graft alloantigens to initiate and effect rejection of donor strain  heart grafts. 
These findings are consistent with the fact that when exposed to donor strain 
antigens,  cells  from  animals  with  enhanced  grafts  can  proliferate  in  mixed 
lymphocyte culture  (MLC)  and  graft-vs.-host  (GVH)  reactions  and  generate 
cytotoxic T  cells with the same vigor as normal lymphocytes (2, 3, 7, 24-26). 
The failure of these alloreactive cells to effect rejection of the enhanced graft 
was explained by the demonstration that  splenic T  cells from these rats  can 
inhibit the capacity of normal lymphocytes to restore graft rejection in irradiated 
hosts. Irradiated rats to which enhancement was transferred were also found to 
have a  state  of specific unresponsiveness that  was  not due to  reinduction of 
enhancement by transfer of a detectable cytotoxic alloantibody response. How- 
ever, these studies did not exclude a possible role for other antibody responses, 
such as antiidiotype or non-complement-fixing alloantibodies, which could block 
alioantigen or opsonize alloantigen-reactive cells, as suggested by Hutchinson 
(27). Even though the removal of B cells in vitro did not remove the capacity of 
spleen cells to adoptively transfer suppression, the possibility cannot be excluded 
that the small (2-5%) contamination with B cells in the in vitro separated T  cell 
population  did not mediate the inhibition.  The failure of sera from rats with 
long-surviving enhanced grafts to induce enhancement of kidney grafts in normal 
recipients (2, 3) or in heart graft-irradiated recipients restored with small num- 
bers (3 ×  107) of normal LNC, argues against a role for antibody (B.  M.  Hall, 
unpublished observation). Furthermore, antiidiotypic antibodies can be demon- 
strated in the induction but not the maintenance phase of enhancement (2,  12) 
and attempts to demonstrate blocking antibody in vitro have also usually failed 
(11). 
As suppressor T  cells in rats with enhanced grafts are not recirculating cells, 
they are quite different from those in  rats with neonatally induced transplant 
tolerance, which can be adoptively transferred with recirculating T  cells. The 
suppressor  cell  in  rats  with  enhanced grafts  has  several other  characteristics 
which suggest that it operates by a different mechanism and against a different 
target than the suppressor T  cell demonstrated in neonatally induced transplant 
tolerance. The suppressor T  cell in neonatal tolerance, unlike that in rats with 
enhanced grafts, leads to effective specific deletion of clones of cells reactive to 
donor antigens in MLC and GVH, as well as those with the capacity to adoptively 
restore rejection of donor strain grafts in irradiated hosts (15). The suppressor 
cells  in  the  spleen  of rats  with  enhanced grafts  were shown to  suppress  the 
ailograft activity of normal LNC populations. However, the suppressor cells from 
transplant-tolerant animals, although capable of specifically suppressing the re- 
generation of alloantigen-sensitive cells in  irradiated hosts, are not capable of 
suppressing the alloreactivity of mature peripheral lymphocytes (15). Finally, the 
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chimeric state  in  these animals,  while  chimerism is  not  a  feature of specific 
unresponsiveness induced in adult animals, including rats with passively enhanced 
grafts (15,  17). 
As our experiments suggested that suppression could only be demonstrated in 
circumstances where the number of normal alloreactive cells was the minimum 
required  to  effect rejection,  it  was  not  surprising  that  previous  attempts  to 
transfer suppression were not successful, as they had transferred spleen cells to 
animals that had sufficient numbers of their own lymphocytes to effect rejection 
of the indicator graft (9,  13,  14).  Batchelor et ai. (28-30) have suggested that 
maintenance  of the  suppressor  state  in  enhancement  is  dependent  upon  a 
reduction in the number of  donor strain dendritic cells within the graft. However, 
this explanation does not account for the fact that the application of donor strain 
skin or organ grafts or the injection of donor strain dendritic cells to animals 
bearing enhanced grafts does not induce a  rejection response against the long- 
surviving graft. In our experiments, the adoptive host was transl~lanted with a 
graft that was immunogenic enough to stimulate as few as 2 ×  10' normal LNC 
to  restore rejection.  Thus,  we surmised that  reduced immunogenicity of the 
graft in  the adoptive host did not contribute to the transfer of enhancement. 
Combining our findings with those of Batchelor et al., it could be concluded that 
adoptive transfer of suppression  in animals with enhanced grafts can only be 
demonstrated when the generation of a  rejection against  the graft  is  limited 
either by the number of alloreactive cells available to mediate rejection or by a 
markedly reduced immunogenicity of the graft. 
The specific unresponsive state seen in animals with enhanced grafts is similar 
in many respects to that seen in animals after treatment with short courses of 
nonspecific immunosuppressives such as ALG (31) or cyclosporin A (17), or by 
active enhancement with  donor  blood  (52)  or  donor  liver extract, Bordetella 
pertussis vaccine, and ALG (16). In all these models, a suppressor T  cell has been 
demonstrated in the spleen that has features in common with the suppressor cell 
demonstrated by our experiments. 
In this report, the results suggest that active suppression, in which T  cells play 
an important role, is a feature of the immune state in,rats that have had prolonged 
allograft survival  induced by passive  enhancement. The  mechanism whereby 
suppressor T  cells operate to prevent the activation of recirculating alloreactive 
T  cells in rats with enhanced grafts is not known. In particular, it remains to be 
answered whether this suppression is directed at helper/inducer T  cell response, 
thus inhibiting delayed-type hypersensitivity-mediated rejection as well as help 
for altoantibody and  cytotoxic T  cell  responses,  or  only against  cytotoxic T 
effector cells (33), and whether suppression operates against responses to MHC 
antigens and minor histocompatibility antigens or only against MHC antigens; 
and the identity of the precise subpopulation of T cells mediating this suppression 
remains to be determined. 
Summary 
DA rats treated with hyperimmune anti-PVG serum and grafted with (DA × 
PVG)Fl heart grafts in which graft survival was prolonged for >75 d were used 
to examine the cellular mechanisms that maintain the state of specific unrespon- BRUCE M.  HALL  131 
siveness found in these animals. The capacity of lymphocytes from these animals 
to effect or inhibit graft rejection on adoptive transfer to irradiated heart-grafted 
hosts was tested. Spleen cell populations and the T  cell suhpopulation separated 
from  spleen  cells  in  vitro  failed  to  restore  rejection  of PVG  heart  grafts  in 
irradiated  DA  recipients  but  restored  third  party  Lew graft  rejection.  Whole 
spleen cells had the capacity to suppress the ability of normal DA LNC to cause 
graft rejection, but T  cells from spleen only delayed the restoration of rejection. 
LNC and recirculating T  cells from rats with enhanced grafts adoptively restored 
PVG rejection, however. These studies show that the state of specific unrespon- 
siveness that follows the induction of passive enhancement is dependent in part 
upon active suppression, which is induced or mediated by T  lymphocytes. The 
recirculating  pool  of lymphocytes in  these  animals  is not  depleted of specific 
alloreactive cells with the  capacity to initiate  and effect rejection.  Thus,  these 
animals'  unresponsiveness  is  not  like  that  found  in  transplantation  tolerance 
induced in neonatal  rats, but is,  in part,  due to a  suppressor response that can 
inhibit normal alloreactive cells' capacity to initiate and effect rejection. 
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the manuscript. 
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